BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 24172843)

  • 1. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J; Chatelain C; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR
    Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS; Chapman K; Swanepoel P; Enjeti AK
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
    J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
    Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
    Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
    Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
    Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
    Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
    Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
    Siriez R; Evrard J; Dogné JM; Pochet L; Gheldof D; Chatelain B; Mullier F; Douxfils J
    Thromb Haemost; 2018 Jul; 118(7):1203-1214. PubMed ID: 29890519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.